525 related articles for article (PubMed ID: 23628617)
1. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
Riddle MC; Aronson R; Home P; Marre M; Niemoeller E; Miossec P; Ping L; Ye J; Rosenstock J
Diabetes Care; 2013 Sep; 36(9):2489-96. PubMed ID: 23628617
[TBL] [Abstract][Full Text] [Related]
2. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).
Riddle MC; Forst T; Aronson R; Sauque-Reyna L; Souhami E; Silvestre L; Ping L; Rosenstock J
Diabetes Care; 2013 Sep; 36(9):2497-503. PubMed ID: 23564915
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).
Ahrén B; Leguizamo Dimas A; Miossec P; Saubadu S; Aronson R
Diabetes Care; 2013 Sep; 36(9):2543-50. PubMed ID: 23536584
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).
Seino Y; Min KW; Niemoeller E; Takami A;
Diabetes Obes Metab; 2012 Oct; 14(10):910-7. PubMed ID: 22564709
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).
Rosenstock J; Hanefeld M; Shamanna P; Min KW; Boka G; Miossec P; Zhou T; Muehlen-Bartmer I; Ratner RE
J Diabetes Complications; 2014; 28(3):386-92. PubMed ID: 24650952
[TBL] [Abstract][Full Text] [Related]
7. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
[TBL] [Abstract][Full Text] [Related]
8. Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
Rosenstock J; Guerci B; Hanefeld M; Gentile S; Aronson R; Tinahones FJ; Roy-Duval C; Souhami E; Wardecki M; Ye J; Perfetti R; Heller S;
Diabetes Care; 2016 Aug; 39(8):1318-28. PubMed ID: 27222510
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.
Liu F; Liu Y; Liu M; Wu G; Zhang M; Zhang X; Cui N; Yin H; Chen L
J Diabetes Investig; 2021 Aug; 12(8):1386-1394. PubMed ID: 33475222
[TBL] [Abstract][Full Text] [Related]
10. Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial.
Meneilly GS; Roy-Duval C; Alawi H; Dailey G; Bellido D; Trescoli C; Manrique Hurtado H; Guo H; Pilorget V; Perfetti R; Simpson H;
Diabetes Care; 2017 Apr; 40(4):485-493. PubMed ID: 28188240
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study.
Seino Y; Ikeda Y; Niemoeller E; Watanabe D; Takagi H; Yabe D; Inagaki N
Horm Metab Res; 2015 Nov; 47(12):895-900. PubMed ID: 26039935
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
Pinget M; Goldenberg R; Niemoeller E; Muehlen-Bartmer I; Guo H; Aronson R
Diabetes Obes Metab; 2013 Nov; 15(11):1000-7. PubMed ID: 23627775
[TBL] [Abstract][Full Text] [Related]
13. Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials.
Hanefeld M; Berria R; Lin J; Aronson R; Darmon P; Evans M; Van Gaal L
Adv Ther; 2014 Aug; 31(8):861-72. PubMed ID: 25143188
[TBL] [Abstract][Full Text] [Related]
14. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial.
Ratner RE; Rosenstock J; Boka G;
Diabet Med; 2010 Sep; 27(9):1024-32. PubMed ID: 20722676
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).
Rosenstock J; Raccah D; Korányi L; Maffei L; Boka G; Miossec P; Gerich JE
Diabetes Care; 2013 Oct; 36(10):2945-51. PubMed ID: 23698396
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme.
Broglio F; Mannucci E; Napoli R; Nicolucci A; Purrello F; Nikonova E; Stager W; Trevisan R
Diabetes Obes Metab; 2017 Feb; 19(2):248-256. PubMed ID: 27762096
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study.
Dailey GE; Dex TA; Roberts M; Liu M; Meneilly GS
J Diabetes; 2019 Dec; 11(12):971-981. PubMed ID: 31094074
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).
Fonseca VA; Alvarado-Ruiz R; Raccah D; Boka G; Miossec P; Gerich JE;
Diabetes Care; 2012 Jun; 35(6):1225-31. PubMed ID: 22432104
[TBL] [Abstract][Full Text] [Related]
19. Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.
Farngren J; Persson M; Ahrén B
Diabetes Care; 2016 Feb; 39(2):242-9. PubMed ID: 26537183
[TBL] [Abstract][Full Text] [Related]
20. Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Meier JJ; Rosenstock J; Hincelin-Méry A; Roy-Duval C; Delfolie A; Coester HV; Menge BA; Forst T; Kapitza C
Diabetes Care; 2015 Jul; 38(7):1263-73. PubMed ID: 25887358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
